compared with the eNOS +/+ non-DM mice, and FXa activity was elevated in the urine collected for 24 hours using metabolic cages from these mice ( Figure 1C and 1D) . Consistent with the report of FX expression in macrophages, 19 vast majority of immunoreactive FX/FXa colocalized with MOMA-2, a macrophage marker, in the glomeruli of the eNOS −/− DM mice ( Figure 1E ). Carbonyl stress with methylglyoxal, which is present in DM, elevated FX expression in peritoneal macrophages ( Figure 1F ). We conclude that macrophage FX in the DM kidney likely contributes to the pathogenesis of DN.
Inhibition of FXa Alleviates DN
Because increased FX and TF likely accelerate DN, we tested whether inhibiting FXa via oral administration of a prescription FXa inhibitor, edoxaban, ameliorates and prevents DN. Edoxaban did not significantly affect blood pressure, kidney weight, and blood glucose levels in the eNOS −/− DM mice ( Table I in the online-only Data Supplement; Figure 2A and 2B). Edoxaban treatment of the eNOS −/− DM mice resulted in a nonsignificant reduction in urinary albumin excretion (215 μg/mg creatinine versus 413 μg/mg in untreated mice; P=0.086; Figure 2C ). Plasma cystatin C concentration in DM mice was lower than that in non-DM mice, probably because of hyperfiltration ( Table I in the online-only Data Supplement). There was no interaction between eNOS genotype and edoxaban treatment ( Figure 2D ). In contrast, edoxaban corrected mesangial matrix score of the eNOS −/− DM mice (28.6% in treated mice versus 32.8% in untreated mice; P<0.001; Figure 2E and 2F), indicating resolution of diabetic glomerulosclerosis.
Inhibition of FXa Corrects Expression of Inflammatory/Fibrotic Genes and PARs
Because FXa induces inflammation, 12, 13 we tested whether FXa inhibitor changes the expression levels of proinflammatory and profibrotic genes (Tgfb, Pai1, Col1, Col4, and Tnfa).
As expected, the expression of these genes was upregulated in the kidneys of the eNOS −/− DM mice ( Figure 3A ; Table II in the online-only Data Supplement). Edoxaban significantly reduced Pai1, Col1, Col4, and Tnfa mRNA levels ( Figure 3A) , supporting the hypothesis that inhibiting FXa alleviates DN in the eNOS −/− DM mice. Therapeutic effects of edoxaban, such as attenuation of urinary albumin excretion, mesangial proliferation, and profibrotic gene expression, were also observed in the heterozygous eNOS +/− DM mice ( Figure IA -ID in the online-only Data Supplement).
Because FXa activates PAR1, and PAR2 and the PARs induce inflammation, 14, 20 we next quantified the expression of the genes encoding PARs in the kidneys. Expression level of Par1 mRNA was significantly higher in the eNOS −/− DM mice than in the eNOS +/+ DM and non-DM mice ( Figure 3B ; Table II in the online-only Data Supplement). That of Par2 was significantly higher in the eNOS −/− DM mice than in the non-DM mice ( Table II in Figure 3B and 3C). Par4 mRNA levels did not differ between genotypes or in response to edoxaban treatment ( Figure 3D ).
Lack of Par2 Alleviates DN
Edoxaban alleviated kidney injury in both eNOS +/− and eNOS −/− DM mice. FXa directly activates PAR2 12, 13 ; thus, if inhibiting PAR2 is beneficial for combating DN, it is worth developing PAR2 antagonists. We therefore investigated whether lack of Par2 ameliorates DN using DM mice lacking Par2 and with reduced eNOS expression (F2rl1 −/− ;Ins2 Akita/+ ;eNOS +/-). The basic characteristics of mice at 7 months of age appear in Table III in Table III in the online-only Data Supplement). DM decreased plasma cystatin C levels, but the absence of Par2 did not affect these levels ( Figure 4D ). Lack of Par2 inhibited glomerular mesangial matrix expansion (26.5% versus 28.9%, P=0.007; Figure 4E and 4F). Lack of Par2 resulted in a nonsignificant reduction in glomerular basement membrane thickness (235 versus 272 nm; P=0.06) and a significant reduction in foot process width (500 versus 573 nm; P=0.02; Figure 4G -4I). Taken together, these data suggest that lack of Par2 alleviates DN.
Lack of Par2 and Gene Expression in the Kidneys
Expression levels of proinflammatory and profibrotic genes (Tgfb, Pai1, Col1, Col4, Tnfa, and Ptgs2) were higher in the eNOS +/− DM kidneys than in the eNOS +/non-DM kidneys ( Figure 5A ). Tgfb, Pai1, Col1, Col4, and Ptgs2 mRNA levels were significantly lower when Par2 was absent ( Figure 5A ). Consistent with results in the eNOS +/+ and eNOS −/− mice ( Figure 1A and 1B), DM in the eNOS +/− mice did not affect plasma FXa activity or liver FX mRNA expression, and Par2 absence also did not affect these values ( Figure 5B and 5C). DM increased kidney FX expression and urinary FXa activity; lack of Par2 did not affect them ( Figure 5D and 5E). DM increased Par1 and Par2 mRNA levels in the kidney, whereas lack of Par2 significantly reduced renal expression of Par1 without affecting that of Par4 ( Figure 5F-5H ). We conclude that lack of Par2, similar to inhibition of FXa, attenuates inflammation and fibrosis in DN. Furthermore, edoxaban and lack of Par2 both decreased expression levels of Tgfb in the kidneys, but they did not have additive effect. Lack of Par2 decreased expression levels of Mcp1 in the kidneys, but edoxaban has no further benefit to diabetic Par2 −/− mice, supporting the linkage of FXa and PAR2 in the pathogenesis of DN ( Figure IIA -IIC in the online-only Data Supplement).
FXa and PAR2 Agonist Exacerbate Inflammation in Endothelial Cells and Podocytes
Ample of studies demonstrated that coagulation factor VIIa/ FXa-PAR2 signaling activates NF-κB and MAPK, major mediators of inflammation. [12] [13] [14] Inflammation plays a pivotal role in the progression of DN. [21] [22] [23] [24] We therefore investigated whether FXa and PAR2 activation directly cause inflammation in endothelial cells and podocytes in vitro. Stimulation of a human endothelial cell line EA.hy926 with FXa (50 nmol/L) or with the PAR2 agonist peptide SLIGKV (100 μmol/L) increased production of interleukin-8 protein and expression of MCP1 and PAI1 ( Figure 6A-6D ). FXa from macrophages that have infiltrated the kidney likely increases PAR2 expression in podocytes ( Figure III in the online-only Data Supplement) and activates PAR2. In conditionally immortalized murine podocytes, we found that FXa increased the expression of the inflammatory mediators Mcp1 and Ptgs2 (that latter of which encodes cyclooxygenase-2), an effect that was reversed by FSLLRY-NH2, a PAR2 antagonist ( Figure 6E and 6F). Another PAR2 agonist, 2f-LIGRLO (20 μmol/L), also increased the expression of Mcp1 and Ptgs2 in podocytes ( Figure 6G ). We conclude that FXa and PAR2 activation directly increase the inflammatory response in endothelial cells and podocytes.
Discussion
Here, we demonstrated that FXa-PAR2 activation exacerbates DN, likely through an enhanced inflammatory response. This conclusion is based on the following major findings: online-only Data Supplement); lack of Par2 ameliorates DN and reduces the expression of profibrotic and proinflammatory genes (Figures 4 and 5A) ; FXa inhibition and lack of Par2 have no additive effect on reduction of inflammatory response ( Figure II in the online-only Data Supplement); and FXa and PAR2 agonist elevate, whereas PAR2 antagonist decreases, levels of inflammatory cytokines in endothelial cells and podocytes ( Figure 6 ). FX is mainly synthesized in the liver. 12, 13 However, increased extrahepatic expression of FX in bronchial/ alveolar epithelia and macrophages contributes to bleomycin-induced lung fibrosis and asthma, respectively. 25, 26 The anti-FX antibody we used recognizes both FX and FXa. Because FX is produced in macrophages, it is likely activated on secretion and works on macrophages in an autocrine manner or on other cells in the kidney in a paracrine fashion ( Figure 1E ). Carbonyl stress that is elevated in DM directly increased FX expression in macrophages ( Figure 1F ). Macrophage infiltration reportedly increased in DN lacking eNOS. 5, 6 The oral FXa inhibitor edoxaban alleviated DN (Figure 2 ). Accordingly, local FX synthesis in macrophages that have infiltrated the kidney likely contributes to the progression of DN.
Increased plasma FXa activity in eNOS −/− mice could be because of increased TF expression on circulating monocytes, which infiltrate in the glomeruli of diabetic mice lacking eNOS as we previously reported. 7 Because macrophages synthesize coagulation factor VII and factor VII-activating protease (FSAP) 27, 28 together with TF and FX, it is highly likely that macrophages in glomeruli can secrete and activate FX. FXa activates PAR1 and PAR2 and stimulates cytokine production. 12, 13 FXa strongly increased the expression levels of Par2 in podocytes in vitro ( Figure III in the online-only Data Supplement). PAR2 expression was also upregulated in the kidney of db/db mice. 29 Interestingly, immunoreactive PAR2, but not PAR1, was higher in biopsy specimens from patients with DN than in specimens from patients without DN. 30 These results support the importance of PAR2 in the pathogenesis of DN. Fondaparinux, a FXa inhibitor, is suggested to reduce DN in db/db mice. 29 We extended this work using another DN model and identified connection between FXa and PAR2.
Inflammation plays a pivotal role in the pathogenesis of DN. [21] [22] [23] [24] Thus, activation of the tumor necrosis factor α pathway predicts DN in humans 23 and deletion or inhibition of MCP1 is protective against DN. 24 Podocyte-derived MCP1 induces podocyte death and increases permeability to albumin, which may underlie the pathogenesis of DN. 31 Cyclooxygenase-2 expression in podocytes is upregulated in DM kidney versus non-DM kidney, and overexpression of cyclooxygenase-2 in podocytes exacerbates DN. 32-34 PAR2 expression was relatively lower than that of PAR1 in murine podocyte. 35 However, we confirmed that stimulation by FXa increased Par2 mRNA, and FXa was increased under diabetic condition (Figure 1 ; Figure III in the online-only Data Supplement). FXa and PAR2 agonist both increased the expression of Mcp1 and Ptgs2 (Figure 6E-6G) , consistent with the hypothesis that inflammation mediates the exacerbation of DN by FXa and PAR2.
Endothelial cells also highly express PAR2. [36] [37] [38] PAR2 stimulates interleukin-8 release in human umbilical vein endothelial cells and human dermal microvascular endothelial cells. 36, 37, 39 Here, both FXa and the PAR2 agonist SLIGKV increased the levels of interleukin-8 protein as well as the expression of the genes encoding MCP1 and PAI1 in the human endothelial cell line EA.hy926 (Figure 6A-6D) . It remains to be determined whether PAR2 in endothelial cells plays a significant role in vivo in the pathogenesis of DN.
FXa is suggested to dysregulate glucose metabolism and upregulate reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase expression in diabetic artery which may be associated with diabetic vascular dysfunction. 40 In our studies, Noxs mRNA expressions were not altered among groups ( Figure IV in the online-only Data Supplement), which is consistent with our previous finding that exacerbation of DN in the absence of eNOS is not associated with oxidative stress marker (reduced and oxidized glutathiones). 6 NADPH oxidases or oxidative stress dose not cause injurious effects in our model. FXa inhibition is known to reduce PAR1 activation and thrombin generation. Our results showed that the levels of Par1 expression increased in the kidney with DN, which was corrected by FXa inhibition and by the absence of Par2 (Figures 3B  and 5F ). PAR1 and thrombin are reportedly proinflammatory and pathogenic in a rodent model of glomerulonephritis and acute kidney injury. 41, 42 However, thrombin is protective against DN at low concentrations of ≈40 nmol/L. Antiapoptotic effect on murine podocytes of activated protein C-PAR1/PAR3 pathway is also shown. 35, 43 Furthermore, PAR2 is also activated by other proteases, DPP4 or Cathepsin S, which could be involved in diabetic complications. 44, 45 We do not exclude the contribution of PAR1, thrombin, or other PAR2 activators in our model. Although FXa inhibition or lack of PAR2 reduced severity of DN, it was not corrected to the levels of non-DM in some parameters, suggesting that other injurious mechanism may exist.
In conclusion, our data suggest that FXa and PAR2 exacerbate DN via inflammation. Several FXa antagonists, including edoxaban, which are prescribed to prevent thromboembolic complications in atrial fibrillation, 46, 47 could be useful as a new therapeutic option for DN, and clinical studies to test their safety and effectiveness will be required. It is worth developing PAR2 inhibitors for preventing DN, and possibly other kidney diseases, because PAR2 inhibition does not cause bleeding complications. PAR2 inhibitors would be useful in combination with angiotensin inhibition, because the effect of the latter is limited because of angiotensin breakthrough. 48 Because no teratogenic effect of Par2 deletion is reported, 49 PAR2 inhibition is expected to be harmless for pregnant woman.
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